MBX Biosciences announced that its once-weekly investigational drug, canvuparatide, achieved the prespecified primary composite endpoint in its Phase 2 Avail trial in patients with chronic hypoparathyroidism, according to the company. In the 12-week randomized period, 63 % of canvuparatide-treated p…
Advancing targeted protein degradation (TPD) depends on a coordinated ecosystem of tools that support target validation, mechanistic interrogation, and translational predictions. The post Targeted Protein Degradation Broadens Its Scope appeared first on GEN - Genetic Engineering and Biotechnology Ne…
Character Biosciences, a precision medicine company focused on ophthalmology, has been selected as one of the “Fierce 15” biotechnology companies for 2025 by Fierce Biotech, according to the company. The designation seeks to highlight private biotech firms with promising science and commercial poten…
From spaceflight to high-throughput studies, evidence supports greater use of organ chips, but regulatory ambiguity and reliance on animal models slow adoption . The post Organ Chips Move Towards Mainstream Drug Development, with Hurdles Ahead appeared first on GEN - Genetic Engineering and Biotechn…
Study highlights functional preservation in patients and signals the potential for pre-symptomatic intervention. For decades Huntington’s disease has stood as both a genetic certainty and a model of accelerated cellular aging; new clinical trial data now show that decline can be delayed. Results rel…
In this June issue Thought Leader article, David A. George of Scripps Laboratories explains why recombinant technologies are the most responsible path to ensuring the continued availability of the tests patients and clinicians rely on every day. The post State of the Diagnostic Industry: Recombinant…
YouthBio receives positive FDA feedback on therapy designed to restore youthful gene expression patterns and address drivers of Alzheimer’s. Epigenetic rejuvenation startup YouthBio Therapeutics has received encouraging feedback from the US FDA on its investigational Alzheimer’s therapy YB002 as it …
YouthBio Therapeutics has received positive feedback from the U.S. Food and Drug Administration (FDA) following an INTERACT meeting regarding its investigational gene therapy, YB002, aimed at treating Alzheimer’s disease. The FDA’s response indicates that existing preclinical data support the bioact…
Macrocycles, de novo antibodies, and mRNA therapies are expanding the drug discovery toolbox for unmet patient needs. The post Novel Therapeutic Modalities Target the Undruggable appeared first on GEN - Genetic Engineering and Biotechnology News.
A new method screens large libraries of synthetic cyclic peptides to identify compounds that can enter cells for therapeutic effect, opening avenues for a modality that combines the properties of a biologic in a pill. The post Macrocyclic Peptide Drugs Unlocked, Membrane Permeability Screened at Sca…
Company targets confirmatory trials of immunomodulator shown to slow cognitive decline when used as a control arm. Longevity biotech Advantage Therapeutics has secured a $2.5 million Phase II Small Business Innovation Research grant from the National Institute on Aging to advance its Alzheimer’s dis…
Investments in neurodegeneration-focused startups set to continue as Sanofi Ventures gets significant cash infusion. Pharma giant Sanofi has revealed it is providing an additional $625 million to Sanofi Ventures, its corporate venture capital arm, with the funds earmarked for investments in early st…
Startup’s ‘brain shuttle’ tech is designed to efficient, repeatable delivery of genetic medicines across the blood–brain barrier. Irish biotech Aerska has emerged from stealth with $21 million in seed financing as it seeks to advance new RNA interference medicines specifically designed to reach the …
Biomed Industries presented Phase 2 clinical data for NA-931—also known as Bioglutide™—at the European Association for the Study of Diabetes (EASD) meeting in Vienna. According to the company, the oral quadruple receptor agonist achieved weight loss comparable to leading injectables, while demonstra…
Promega’s nonlytic, bioluminescent bioassay platform that distinguishes bystander from direct cytotoxicity in a single co-culture experiment. The post Measuring Direct, Bystander, and Off-Target ADC Killing with the HiBiT TCK Platform appeared first on GEN - Genetic Engineering and Biotechnology New…
Throughput is no longer the bottleneck. Sensitivity is. A platform that captures only a fraction of transcripts per cell fails to detect lower-abundance populations that define an atlas’s resolution and utility. The post Spatial Atlasing: Why Sensitivity Is the Real Frontier appeared first on GEN - …
In early discovery, researchers use high-throughput screening (HTS) to identify active compounds in a biologically relevant context. During lead characterization and validation, these assays generate reproducible, quantitative data to confirm activity and support candidate selection. In later stages…
Trump's Truth Social post comes as air strikes between the U.S. and Iran resumed over the weekend.
Chrysea and KaloCyte have entered into an exclusive strategic alliance intended to accelerate development and deployment of a biosynthetic red blood cell substitute for medical emergencies. According to the companies, Chrysea will apply its synthetic biology platform in conjunction with KaloCyte’s a…
Longevity biotech seeks to broaden its therapeutic capabilities with cellular reprogramming and delivery technologies. UPDATE: On October 7th, 2025, Klotho Neurosciences announced that its Letter of Intent to acquire assets from Turn Biotechnologies was allowed to expire. The company said its Board …
